RELATIVE PROGRESSION-FREE SURVIVAL OVER TIME OF NOVEL TRIPLET REGIMENS FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Betts, K. [1 ]
Chen, C. [2 ]
Zichlin, M. [1 ]
Brun, A. [2 ]
Signorovitch, J. [1 ]
Makenbaeva, D. [2 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Bristol Myers Squibb Inc, Plainsboro, NJ USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1300
引用
收藏
页码：533 / 533
页数：1
相关论文
共 50 条
  • [41] Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
    Fotiou, Despina
    Gavriatopoulou, Maria
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [42] Cost per median month of progression-free survival for daratumumab plus bortezomib and dexamethasone compared with carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma.
    Maiese, Eric
    Graham, Christopher N.
    Hawe, Emma
    Le Moine, Jean-Gabriel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma
    Lakshman, Arjun
    Singh, Preet Paul
    Rajkumar, S. Vincent
    Dispenzieri, Angela
    Lacy, Martha Q.
    Gertz, Morie A.
    Buadi, Francis K.
    Dingli, David
    Hwa, Yi Lisa
    Fonder, Amie L.
    Hobbs, Miriam
    Hayman, Suzanne R.
    Zeldenrust, Steven R.
    Lust, John A.
    Russell, Stephen J.
    Leung, Nelson
    Kapoor, Prashant
    Go, Ronald S.
    Lin, Yi
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Warsame, Rahma
    Kyle, Robert A.
    Kumar, Shaji K.
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (02) : 179 - 186
  • [44] Genomic Predictors of Progression-Free Survival Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial
    Pelham, Robert J.
    Hu, Xuguang
    Moreau, Philippe
    Oriol, Albert
    Quach, Hang
    Kovacsovics, Tibor
    Keats, Jonathan J.
    Feng, Shibao
    Kimball, Amy S.
    Dimopoulos, Meletios A.
    BLOOD, 2017, 130
  • [45] PROGNOSTICATION OF RESPONSE TO BORTEZOMIB, PROGRESSION FREE AND OVERALL SURVIVAL IN RELAPSED/REFRACTORY MYELOMA PATIENTS
    Kyrtsonis, M. C.
    Vassilakopoulos, T. P.
    Sachanas, S.
    Panagoulias, G.
    Bartzis, V.
    Anargyrou, K.
    Dimou, M.
    Tzenou, T.
    Masouridis, S.
    Kalpadakis, C.
    Dimitrakopoulou, E.
    Kokoris, S. I.
    Dimitriadou, E.
    Siakantaris, M. P.
    Angelopoulou, M. K.
    Panayiotidis, P.
    Pangalis, G. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 263 - 263
  • [46] Duration of Treatment of Multiple Myeloma Regimens in Patients with Relapsed or Refractory Multiple Myeloma: Findings in US Clinical Practice Settings
    Potluri, Ravi
    Kanakamedala, Hemanth
    Chen, Clara
    Yasenchak, Christopher A.
    Ranjan, Sandip
    Papademetriou, Eros
    Bhandari, Hitesh
    Mann, Jasdeep
    Davis, Catherine
    BLOOD, 2017, 130
  • [47] The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis
    Liao, K-Y
    Liu, Y.
    Xiong, H.
    Chen, X-M
    Zhang, X-W
    Huang, C-L
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (21) : 8087 - 8097
  • [48] Refractory Multiple Myeloma Doubling progression-free Survival for Elotuzumab in Combination with Pomalidomide and Dexamethasone in the ELOQUENT-3 Study
    Freyer, Martina
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (7-8) : 390 - 391
  • [49] Comparative Effectiveness of Lenalidomide/Dexamethasone-Based Triplet Regimens for Treatment of Relapsed and/ or Refractory Multiple Myeloma in Subgroups Defined By Cytogenetic Risk
    Sanchez, Larysa
    Cheng, Mu
    Cherepanov, Dasha
    DerSarkissian, Maral
    Stull, Dawn Marie
    Huang, Fei
    Hilts, Annalise
    Chun, Justin
    Duh, Mei Sheng
    Ailawadhi, Sikander
    BLOOD, 2022, 140 : 4308 - 4309
  • [50] Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint
    Rosenberg, Aaron S.
    Facon, Thierry
    Parikh, Kejal
    Chung, Weiyuan
    Srinivasan, Shankar
    Kotey, Stanley
    Tuscano, Joseph
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (05): : 345 - +
12345